| Drug General Information |
| Drug ID |
D07NYF
|
| Former ID |
DIB005893
|
| Drug Name |
MLN-2201
|
| Synonyms |
LDP-01; MLN-01; Anti-beta2-integrin MAb, LeukoSite
|
| Drug Type |
Antibody
|
| Indication |
Cerebrovascular ischaemia [ICD9: 434.91; ICD10:I61-I63]
|
Discontinued in Phase 1 |
[1]
|
|---|
| Company |
LeukoSite Inc
|
| CAS Number |
CAS 339164-13-5
|
| Target and Pathway |
| Target(s) |
Integrin beta-2 |
Target Info |
|
[2]
|
|---|
|
KEGG Pathway
|
Rap1 signaling pathway
|
|
Phagosome
|
|
Hippo signaling pathway
|
|
Cell adhesion molecules (CAMs)
|
|
Natural killer cell mediated cytotoxicity
|
|
Leukocyte transendothelial migration
|
|
Regulation of actin cytoskeleton
|
|
Pertussis
|
|
Legionellosis
|
|
Leishmaniasis
|
|
Malaria
|
|
Amoebiasis
|
|
Staphylococcus aureus infection
|
|
Tuberculosis
|
|
HTLV-I infection
|
|
Rheumatoid arthritis
|
|
Viral myocarditis
|
|
NetPath Pathway
|
IL5 Signaling Pathway
|
|
TCR Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Integrin signalling pathway
|
|
Pathway Interaction Database
|
Integrin family cell surface interactions
|
|
amb2 Integrin signaling
|
|
Beta2 integrin cell surface interactions
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
CXCR3-mediated signaling events
|
|
HIF-1-alpha transcription factor network
|
|
Reactome
|
Toll Like Receptor 4 (TLR4) Cascade
|
|
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
|
Cell surface interactions at the vascular wall
|
|
Integrin cell surface interactions
|
|
WikiPathways
|
Focal Adhesion
|
|
Human Complement System
|
|
Toll-Like Receptors Cascades
|
|
Integrin-mediated Cell Adhesion
|
|
Integrin cell surface interactions
|
|
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
|
Cell surface interactions at the vascular wall
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010178) |
|---|
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010178) |
|---|
